Scroll to top
Tag: CBT
03/08/2023

Cognitive Behavioral Therapy Mobile App Improves Health Behavior in Patients with Diabetes

Article Excerpt: With the use of cognitive behavioral therapy, a smartphone app helped patients with type 2 diabetes reduce HbA1c with less medication and insulation intensification vs. controls, a speaker reported. “Cardiometabolic diseases, and at its core, type 2 diabetes, are largely behavioral-acquired diseases and they’re related to unhelpful behaviors. But when we drive to what are the core, root causes of these behavioral choices, they have to do with thoughts and beliefs that lead to unhelpful behaviors and then unhelpful food choices, eating, exercise or behaviors and then type 2 diabetes,” Marc P. Bonaca, MD, MPH, FAHA, FACC, executive director of CPC Clinical Research, professor of cardiology and vascular medicine and director of vascular research at the University of Colorado School of Medicine, said during a press conference. “How do we break that cycle?

Full Article: https://tinyurl.com/2s4ht3rj

Article Source: Healio

02/10/2023

CBT Smartphone App Aims to Address Depression in Teens

Article Excerpt: Researchers recently created a brand new CBT smartphone app that will provide young people with multiple ways to address and handle their mental health problems. A study group will now be assembled to assess the effectiveness of the smartphone application in relation to its ability to combat depression. Adolescents are struggling with depression at higher rates today than ever before. Researchers believe that the stress of the coronavirus pandemic and the resulting peer isolation and disruption to school life is to blame. Other factors cited include an ever-growing presence on social media and pressure to conform to impossible celebrity standards. Thus, any way in which technology can help depressed teens minimize symptoms is much-needed. Through the use of interactive and self-guided therapy, the ClearlyMe app will use the power of cognitive behavioral therapy, or CBT, on teenagers from all over the country. The technology contains 37 “short lessons” that will touch upon the basics of CBT and the power it has to change thinking and alter core beliefs in those who use it.

Full Article: https://tinyurl.com/326u5s8v

Article Source: Legal Reader

10/10/2022

Therapist-guided internet-based psychodynamic therapy versus cognitive behavioural therapy for adolescent depression in Sweden: a randomised, clinical, non-inferiority trial

Mechler J, Lindqvist K, Carlbring P, Topooco N, Falkenström F, Lilliengren P, Andersson G, Johansson R, Midgley N, Edbrooke-Childs J, Dahl H-S J, Sandell R, Thorén A, Ulberg R, Bergsten KL, & Philips B. (2022). Therapist-guided internet-based psychodynamic therapy versus cognitive behavioural therapy for adolescent depression in Sweden: a randomised, clinical, non-inferiority trial. The Lancet (British Edition), 4(8), e594–e603. https://doi.org/10.1016/S2589-7500(22)00095-4

This study compared internet-based psychodynamic therapy (IPDT) with an established evidence-based treatment (internet-based cognitive behavioral therapy (ICBT)) for adolescents with depression. Participants aged 15-19 years with a diagnosis of major depressive disorder (N=272) were recruited in Sweden and randomly assigned to receive IPDT or ICBT. Both online interventions consisted of 8 self-help modules delivered over 10 weeks. Modules contained text, videos, and interactive exercises. All participants were also offered 30 minutes of weekly therapist support via live chat. The primary outcome was change in depression severity measured weekly by a brief self-report measure (Quick Inventory of Depressive Symptomatology ()). Participants in both groups showed similar engagement levels and high completion rates (defined as completing at least five modules and chat sessions and post-treatment assessment). Depressive symptoms in both groups significantly improved during treatment. At the end of treatment, demonstrated that IPDT was non-inferior to ICBT in the treatment of depression for adolescents. Results contribute to the evidence base for feasibility of online delivery of both IPDT and ICBT for the treatment of depression among a late-adolescent population.

09/19/2022

The Efficacy of “Foundations,” a Digital Mental Health App to Improve Mental Well-being During COVID-19: Proof-of-Principle Randomized Controlled Trial

Catuara-Solarz S, Skorulski B, Estella-Aguerri I, Avella-Garcia C, Shepherd S, Stott E, Hemmings N, Ruiz de Villa A, Schulze L, Dix S. The Efficacy of “Foundations,” a Digital Mental Health App to Improve Mental Well-being During COVID-19: Proof-of-Principle Randomized Controlled Trial. JMIR Mhealth Uhealth 2022;10(7):e30976 DOI: 10.2196/30976

This study aimed to evaluate the efficacy of a mobile app, “Foundations”, to reduce self-reported symptoms of anxiety and stress in a randomized control trial during the COVID-19 pandemic in the United Kingdom. Adults (N=136) with mild to severe anxiety and moderate to high levels of perceived stress were randomly assigned to four weeks of the Foundations app or a waitlist control. The Foundations app includes cognitive behavioral therapy interventions and psychoeducation aimed at reducing stress and promoting mental well-being. Activities consist of reading articles, journaling, meditation, and relaxation. Resilience, anxiety, well-being, and sleep were assessed at baseline, weeks 2 and 4. Perceived stress was assessed weekly. The intervention group (n=62) showed significant improvement in anxiety (p=0.04), resilience (p<0.001), sleep (p=0.01), and mental well-being (p=0.02) compared to the control group (n=74). This improvement was observed within 2 weeks of the intervention and sustained at week 4. There was no significant difference in perceived stress between the intervention and control groups (p=0.20). Overall, this study provides a proof of principle that the Foundations app may improve mental well-being, anxiety, resilience, and sleep. Future research should evaluate the long-term effects of the Foundations app and the scalability and cost-effectiveness of the intervention. The passive nature of the control group in this study does not rule out placebo effects in the digital intervention group and future research would benefit from an active control condition.

08/16/2022

The Strange, Nervous Rise of the Therapist Chatbot

Article Excerpt: When Nicholas Jacobson and his team test their mental health chatbot, nine out of 10 of its responses are contextualized and clinically appropriate. One in 10 are “weird and lack human-ness,” he told The Daily Beast. This means TheraBot is moving in the right direction. It’s better than when it said, “I want my life to be over” when Jacobson and his team were training the chatbot to use language from self-help internet forums; or when it picked up the bad habits of therapists when they trained it with psychotherapy transcripts—like quickly attributing problems to the user’s relationship with their parent.

Full Article: https://tinyurl.com/n7c5hc87

Article Source: The Daily Beast

08/12/2022

AI Could Help Patients with Chronic Pain Avoid Opioids

Article Excerpt: Cognitive behavioral therapy is an effective alternative to opioid painkillers for managing chronic pain. But getting patients to complete those programs is challenging, especially because psychotherapy often requires multiple sessions and mental health specialists are scarce. A new study suggests that pain CBT supported by artificial intelligence renders the same results as guideline-recommended programs delivered by therapists, while requiring substantially less clinician time, making this therapy more accessible.

Full Article: https://tinyurl.com/bfen88ad

Article Source: University of Michigan News

08/01/2022

Digital Therapeutic Improves Symptoms of Insomnia, Anxiety, Depression for 6 Months

Article Excerpt: Data from a real-world study revealed that treatment with prescription digital therapeutic Somryst achieved reductions in symptoms of insomnia, anxiety and depression, per a late-breaking poster at the SLEEP meeting.Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia, manufacturer Pear Therapeutics stated in a related press release. “Chronic insomnia is often associated with depression and anxiety so it’s important to evaluate the impact of insomnia treatment on such psychiatric comorbidities,” Yuri Maricich, MD, MBA, Pear Therapeutics chief medical officer and head of development, said in the release.

Full Article: https://tinyurl.com/3drnwpnx

Article Source: Healio

07/12/2022

Digital Therapeutic for Substance Use Disorder Drives Down Care Utilization, Cost

Article Excerpt: Digital therapeutics firm Pear Therapeutics has released new data showing its prescription substance use disorder (SUD) therapy reduces hospitalizations and lowers healthcare costs for patients. The data will be published in the journal Advances in Therapy, but the findings are currently available online as a pre-print. The treatment is called reSET. The app is built around cognitive behavioral therapy (CBT) utilizing the community reinforcement approach (CRA), the company said. It includes a 12-week course of therapy, in which patients are incentivized for completing lessons and abstaining from drug use. The app also includes fluency training designed to reinforce the lesson content. Previous studies have shown the therapy can be effective at improving rates of abstinence and treatment retention when coupled with usual treatments. In the new report, investigators wanted to know how such improvements might translate into changes in healthcare resource utilization and costs.

Full Article: https://tinyurl.com/ybezxs3e

Article Source: Managed Healthcare Executive

05/23/2022

Wysa Receives FDA Breakthrough Designation for CBT Tool

Article Excerpt: Wysa, an artificial intelligence (AI) based digital companion for behavioural health, has been granted Breakthrough Device Designation by the Food and Drug Administration (FDA) for its AI-based digital mental health conversational agent for patients 18 years and older with a diagnosis of chronic musculoskeletal pain (defined as pain lasting longer than three months) and depression and anxiety. The device delivers cognitive behavioural therapy (CBT) via a smartphone-based conversational agent to reduce the symptoms of depression and anxiety, reduce pain interference, and improve physical function.

Full Article: https://tinyurl.com/2kz3nvsk

Article Source: Med-Tech Innovation News